en · de · es · fr · pt
selank-notes.peptides6088.com › Data › Proposed Mechanisms And Research Endpoints — Explained

Proposed Mechanisms And Research Endpoints — Explained

By Editorial Desk · published 2026-07-24 · last reviewed 2026-08-01 · Data

Pro-Gly-Pro is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Proposed Mechanisms and Research Endpoints

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

Selank at a glance

PropertyValueNotes
Principal proposed targetGABA-A receptor complexHypothesis derived mainly from animal pharmacology
Common behavioral assayElevated plus mazeRodent test for anxiety-like behavior
Reported molecular markerHippocampal BDNF expressionMeasured by immunoassay or mRNA quantification
Typical dosing routeIntranasalChosen to reduce first-pass metabolism
Reported plasma half-lifeMinutesBased on limited peptide stability data

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Related pages on this site

Administration, Testing and Availability

Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Analytical Methods and Handling

Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.

Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.

Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.

Origins and Proposed Mechanisms

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Notes from published material

"Bad and Boujee" is a song by American hip-hop group Migos featuring American rapper Lil Uzi Vert. Written alongside producer Metro Boomin and co-producer G Koop, it was originally released to the Quality Control Music YouTube channel on August 27, 2016 before being officially released on October 28 by Quality Control Music, 300 Entertainment, and Atlantic Records as the lead single from the group's second studio album Culture (2017). In late December 2016, "Bad and Boujee" became an Internet phenomenon, spawning many memes with the lyrics "rain drop, drop top". This viral trend, combined with Donald Glover's shoutout at the 2017 Golden Globes, would help its commercial performance and cause the song to spike into the top ten and later peak at number one on the US Billboard Hot 100 for the week of January 21, 2017, making it the first number one single for both Migos and Lil Uzi Vert. There were also many memes about member Takeoff's omission from the song. The single received a nomination for Best Rap Performance at the 60th Annual Grammy Awards. The track has acquired over 1 billion Spotify plays as of August 2025.

== Alleged ruthenium-106 leak == In September 2017 an estimated amount of 100 to 300 TBq (0.3 to 1 g) of 106Ru was released in Russia, probably in the Ural region. It was, after ruling out release from a reentering satellite, concluded that the source was either in nuclear fuel cycle facilities or radioactive source production. In France levels up to 0.036mBq/m3 of air were measured. It was estimated that for distances of the order of a few tens of kilometres, contamination levels may have exceeded the limits for non-dairy foodstuffs.

Given the increased expression of Hsp70 in cancer, it has been suggested as a biomarker for cancer prognostics, with high levels portending poor prognosis. An oncogenic mechanism illustrates how extracellular vesicles expressing HSP70 are produced by proliferative Acute Lymphoblastic Leukemia cells and can target and compromise a healthy hematopoiesis system during leukemia development.

=== 21st century === In 2007, the 500th store opened in Seattle, Washington, and in 2010, the 1,000th opened in Beaverton, Oregon. As of March 2017, Jimmy John's had almost 3,000 stores with plans for expansion up to 5,000 and beyond. Liautaud realized that, in order to grow, he would need help acquiring better locations for his stores. Since he had little expertise in real estate, he decided to take on a partner who did. In January 2007, Liautaud sold a 33% stake to Weston Presidio, a San Francisco–based private-equity firm. In the first year after partnering with Weston Presidio, 100 real estate deals were closed. The company has completed two recapitalizations since Weston Presidio's investment. In the summer of 2015, pictures of Liautaud posing with big game circulated on social media, leading to increased calls to boycott his restaurants. In a 2015 interview with the Chicago Tribune, Liautaud said, "I don't hunt big African game anymore." In September 2016, Jimmy John's announced that Roark Capital Group had agreed to acquire a majority stake in the company. Terms of the transaction were not immediately disclosed, though it was later clarified that Liautaud retained 35% ownership of the company as part of the deal. As part of the agreement, Liautaud would continue as chairman of the board. On September 25, 2019, Inspire Brands (affiliated with Roark Capital Group) announced that it was buying Jimmy John's for an unspecified amount in a deal unanimously approved by Liautaud and the rest of the Jimmy John's board of directors.

Sources: en.wikipedia.org

Background from the literature

Evelyn Greechan, Senior Traffic Warden, City of Glasgow Police. For services to Road Safety. Ian Greenlaw, Support Grade Band 1, Her Majesty's Customs and Excise. Brian Gregory, Facilities Manager, Sussex Police. For services to the Police. Sylvia Gladys Grove, Office Support Grade Band 2, Home Office. Alan Joseph Gruar, Training Manager, Lucas Aerospace, Wolverhampton Training Centre, LucasVarity plc. For services to Training. Leslie Gurney. For services to the community in Stockport, Cheshire. Jessie Haggarty. For services to Highland Dancing. Jonathan Ian Hague, Detective Inspector, Metropolitan Police. For services to the Police. Alfred Hall. For services to the World Ploughing Organisation. Arthur Charles Hall. For services to the community in Walton-on-Thames, Surrey. Eileen Hall, Administrative Officer, Department of Social Security. Edna Hilda Knight Hallatt, Governor, Newcastle-under-Lyme School, Staffordshire. For services to Education. Mae Hamilton, Administrative Officer, Home Office. Brenda Margaret Hancock, lately Personal Secretary, Health and Safety Executive, Department of the Environment Angela Kathenne Hanley, Training Manager, First Aid Centre, London Transport. For services to Public Transport. Hilda Harding. For services to Mind and to the Elderly and Disadvantaged in Sutton, Surrey. Anthony Shannon Harman. For services to Agriculture and to the British Charolais Cattle Society. Susan Gladys Harper, Practice Nurse (Sister), Roslin Medical Centre, Midlothian. For services to Health Care. David Harris.

=== Early political career === According to Lad's published biography, he began his political career through the Sandur municipal council in 2002. He contested the 2004 Karnataka Legislative Assembly election from the Sandur constituency as a candidate of the Janata Dal (Secular). He defeated Congress candidate V. Y. Ghorpade, receiving 65,600 votes against Ghorpade's 30,022, a margin of 35,578 votes. Lad subsequently joined the Indian National Congress in 2007.

Powell, one of Eddy's biographers, wrote in 1907 that Quimby's son held an almost identical copy, in Quimby's wife's handwriting, of the Quimby manuscript that Eddy had used when teaching Sally Wentworth. It was dated February 1862, eight months before Eddy met Quimby. In July 1904 the New York Times obtained a copy of the Quimby manuscript from Sally Wentworth's son, and juxtaposed passages with Science and Health to highlight the similarities. It also published Eddy's handwritten notes on Quimby's manuscript to show what the newspaper alleged was the transition from his words to hers. Quimby's manuscripts were published in 1921. Eddy's biographers continued to disagree about his influence on Eddy. Bates and Dittemore, the latter a former director of the Christian Science church, argued in 1932 that "as far as the thought is concerned, Science and Health is practically all Quimby," except for malicious animal mesmerism. Robert Peel, who also worked for the church, wrote in 1966 that Eddy may have influenced Quimby as much as he influenced her. Gardner argued in 1993 that Eddy had taken "huge chunks" from Quimby, and Gill in 1998 that there were only general similarities.

Sources: en.wikipedia.org

Frequently asked questions

How is Selank administered in studies?

Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.

What endpoints do researchers measure?

Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.

What are the main evidence gaps?

Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.

What is the primary sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.

Network